Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

10.80 +0.44 (+4.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kazia Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, trader! We're starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch! 
Via InvestorPlace
Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
Via Benzinga
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug... 
Via iCrowdNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Kazia Therapeutics (KZIA) Stock Soars on FDA Designation
Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. 
Via InvestorPlace
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate
The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ: KZIA) lead drug Paxalisib for the treatment of atypical... 
Via Benzinga
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address... 
From Edison Investment Research Limited
Via AccessWire
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer
Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma. 
Via Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential... 
From Edison Investment Research Limited
Via AccessWire
A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients
Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,... 
Via Benzinga
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly... 
From Edison Investment Research Limited
Via AccessWire
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for... 
From Edison Investment Research Limited
Via AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.